Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

CELLINK has entered into an agreement to acquire the advanced robotics and diagnostics automation company Ginolis

CELLINK AB (publ) ("CELLINK") has entered into an agreement with the shareholders of Ginolis Oy ("Ginolis"), a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries, to acquire all shares for a purchase price on cash- and debt-free basis of 70M euros (the "Acquisition"). Forty percent of the purchase price will be paid in newly issued shares of series B in CELLINK (the “Consideration Shares”) and the remaining purchase price in cash. CELLINK’s Board of Directors will resolve to issue the Consideration Shares in accordance with

Axactor SE - Acceptances received under mandatory offer

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Reference is made to the mandatory offer dated 29 January 2021 (the "Mandatory Offer") to acquire all shares in Axactor SE (the "Company") at an offer price of NOK 8.00 per share, made by Geveran Trading Co. Limited, a company indirectly controlled by trusts established by Mr. John Fredriksen for the benefit of his immediate family ("Geveran").  On 12 February 2021,

TRADING UPDATE Q4-2020 FINANCIAL RESULTS

Oslo, Norway (15 February 2021) — In connection with the voluntary offer by Lesaffre being announced this morning, NattoPharma hereby announces the following key financials for Q4 2020 and FY 2020: Q4 2020 revenue and adj. EBITDA amounts to NOK 62.3m and NOK 14.4m, respectively (adj. EBITDA margin of 23.1%). FY 2020 revenue and adj. EBITDA amounts to NOK 214.5m and NOK 37.3m, respectively (adj. EBITDA margin of 17.4%). NattoPharma will release the Q4 2020 report on 17 February 2021. The presentation will be held as earlier communicated at 10:00 AM CET that same day. However, there

L2 Fastigheter moves up a gear with Wallenstam

Wallenstam has signed a lease with L2 Fastigheter for 420 square meters at Vasagatan 43 B in Gothenburg. In October, they will move into their new office premises in the Avenyn area.L2 Fastigheter is a development-focused property company based in Gothenburg. The company was founded in 2013 and today owns properties in Gothenburg, Borås and Mölndal Municipality. They are already a tenant of Wallenstam and will now move up a gear to a larger office space on two floors high up at Vasagatan 43 B.“It feels extremely nice to welcome L2 Fastigheter to the Avenyn area during the fall. It is

Intention to launch a cash tender offer to acquire 100% of the shares of Kaydence Pharma AS

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Oslo, 15[th] February 2021: Reference is made to the stock exchange disclosure by Nattopharma ASA ("NattoPharma") on 15[th] February 2021 regarding NattoPharma entering into a transaction agreement (the "Transaction Agreement") with Compagnie des Levures Lesaffre ("Lesaffre") under which Lesaffre will launch a recommended voluntary cash tender offer (the "Nattopharma Offer") to acquire 100% of the shares of

Goldman Sachs funds to acquire a majority stake in Advania

· Funds managed by Goldman Sachs Merchant Banking Division are to acquire a majority of the shares in Advania AB, alongside management, VIA Equity and other reinvesting shareholders. · Advania, with a heritage dating back to its inception in Iceland in 1939, is a leading IT-provider in Northern Europe with operations in Sweden, Iceland, Norway, Denmark and Finland. · The company has delivered in excess of 20% growth each of the last 5 years, fueled by strong talent, long term relationships with customers and ongoing megatrends of digitalization. · Advania’s turnover is today in

Össur hf: Annual General Meeting 8 March 2021

Announcement no. 04/2021 15 February 2021  Annual General Meeting 8 March 2021 Össur hf.'s Annual General Meeting will be held on Monday 8 March 2021 at 9:00 am (GMT) The Board of Directors has decided to utilize the authorization in Article 17 of Company’s Articles of Association to have the Annual General Meeting fully virtual. Enclosed the convocation, which includes the proposed agenda for the Annual General Meeting and information on shareholders’ participation and registration, shareholders’ rights, voting and proxies, and other practical matters, as well as the

Hexagon launches R-evolution, a new business venture focused on a sustainable future

Hexagon AB, a global leader in sensor, software and autonomous solutions, today announced the launch of a new business venture focused on reinventing how industry addresses complex environmental challenges: R-evolution.R-evolution is founded to accelerate the transition to a sustainable economy, running profit-driven investments in green-tech projects where Hexagon’s technology can be applied. The move to form R-evolution comes on the heels of Hexagon’s recent announcements to further develop its sustainability agenda, including climate goals to significantly reduce its own carbon

Board of Directors of NattoPharma recommends voluntary cash offer by Lesaffre to acquire all shares in NattoPharma

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Oslo, 15[th] February 2021: Reference is made to the press release dated 2 June 2020 regarding the strategic review of NattoPharma ASA ("NattoPharma" or the "Company") and the engagement of ABG Sundal Collier ASA to investigate various alternatives to maximize shareholder values. Compagnie des Levures Lesaffre (“Lesaffre” or the “Offeror”) and NattoPharma hereby announce that Lesaffre will launch an offer to

DESENIO INTENDS TO CARRY OUT A PRIVATE PLACEMENT AND SUBSEQUENT LISTING OF ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET

NOT FOR PUBLICATION, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, HONG KONG, CANADA, NEW ZEALAND, JAPAN, SWITZERLAND, SOUTH KOREA OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE FURTHER REGISTRATION MEASURES. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Desenio Group AB (publ) (“Desenio” or the “Company”), a fast growing online-based direct-to-consumer (“DTC”) company within the global market for affordable wall art, hereby announces its intention to carry out a

Episealer®: Clinical results with 5-years’ follow-up data to be presented at the 3rd World Arthroplasty Congress

Episurf Medical (Nasdaq: EPIS B) today announces that the scientific report "Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years” by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, has been accepted for presentation at the 3rd World Arthroplasty Congress. The congress is arranged as a digital meeting on April 22-24, 2021. The presentation will be included in the ePosters Knee Session and focuses on clinical results from the use of the Episealer® knee implant.  “This is a great milestone for us

Nitro Games Oyj: Year-end report January – December 2020

Reporting period January – December 2020 · Revenues (Jan-Dec): 1 171,3 KEUR (816,2 KEUR on corresponding period 2019). · EBITDA: -2 326,6 KEUR (-2 658,3 KEUR). · EBIT: -2 783,2 KEUR (-3 284,5 KEUR). · Net profit: -2 810,9 KEUR (-3 293,3 KEUR). · Cash and cash equivalents: 2 981,7 KEUR. October – December 2020 · Revenues (Oct - Dec): 85,8 KEUR (426,6 KEUR). · EBITDA: -877,2 KEUR (-554,6 KEUR). · EBIT: -991,4 KEUR (-711,0 KEUR). · Net profit: -1 004,2 KEUR (-712,0 KEUR). Significant events during October – December 2020 · Nitro Games to develop Nerf

Stora Enso shares converted

STORA ENSO OYJ STOCK EXCHANGE RELEASE 15 February 2021 at 9.00 EET During the 1 January 2021 – 31 January 2021 conversion period there was one conversion and a total of 100 A shares were converted into R shares. The shares were recorded in the Finnish trade register today, 15 February 2021, and trading in the new R shares will start on 16 February 2021.Breakdown of shares after conversion:  A shares 176 254 315R shares 612 365 672Total 788 619 987  Each A share and each ten R shares carry one vote. The total amount of votes after the conversion is at least 237 490

Exercise of employee share options in Atea ASA ("the Company")

Reference is made to the stock announcement dated 10 February 2021.The share capital increase has been registered by the Norwegian Register ofBusiness Enterprises (Foretaksregisteret), and Atea's Articles of association have been revised accordingly. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Trading Act).   For further information, please contact: Robert Giori, CFO Atea ASA, mobile (+47) 934 09 188Ole Johan Fjellestad, Group Chief Accountant Atea ASA, mobile (+47) 992 74 829

10 guidelines for the promotion of equality in recruitment

Recruitment practices promoting diversity may prove to be a practical solution to the lack of applicants while also reducing unintentional discrimination.Press release by the Finnish Institute of Occupational Health  Discrimination in the recruitment process can be prevented by reforming recruitment practices. Recruitment practices promoting diversity  were published in the Manifold More project of the Finnish Institute of Occupational Health.The practices can increase the diversity sought after by workplaces among

Invent Medic begins market activities in the United States through application for registration of Efemia Bladder Support

Invent Medic announces that the company has submitted an application to FDA for 510(k) market registration of the product Efemia bladder support in the United States. Invent Medic expects to be able to present marketing and sales plans for the product in the United States later in 2021.The overall plan for the company's establishment in the United States is proceeding according to plan. The application for market registration is the beginning of marketing activities in the United States for cooperation on the launch of Efemia bladder support. These establishment plans now also include in

People with and without Alzheimer’s have a different threshold for elective revascularisation, but outcomes are similar

The risk of both mortality and rehospitalisation after an elective revascularisation procedure for coronary artery disease is similar for people with and without Alzheimer’s disease (AD), but people with AD had worse outcomes after an emergency procedure, according to a new study from the University of Eastern Finland. Previous studies have investigated the effectiveness of revascularisation in persons with cognitive disorders, but only in terms of short-term outcomes and in acute care settings, and they also have not accounted for electivity. Similar to previous studies, people with

Invitation to the presentation of Elekta’s third quarter 2020/21

SWEDEN, February 15, 2021 – Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the third quarter 2020/21 at 10:00 a.m. CET on February 25. The interim report for the third quarter will be published at 7:30 a.m. CET on the same day. The company’s development will be presented by Elekta’s President and CEO Gustaf Salford together with acting CFO Johan Adebäck. After the presentation, held in English, a Q&A session will follow. The presentation will be broadcasted live on the web. It will be necessary to join the phone conference if you plan to ask questions. A

Year-end report January–December 2020

JANUARY–DECEMBER 2020 · Income amounted to MSEK 2,035 (1,370), an increase of 46%. · Profit from property management amounted to MSEK 1,334 (1,112), an increase of 20%. · Profit from property management excluding changes in value and tax in joint ventures amounted to MSEK 1,145 (814), an increase of 41%. · Distributable cash flow per share amounted to SEK 6,71 (4.73), an increase of 42%. · Profit after tax amounted to MSEK 2,225 (1,382). · Profit after tax per share amounted to SEK 12.25 (8.24). OCTOBER–DECEMBER 2020 · Income amounted to MSEK 559 (383), an

New knowledge about a cancer pharmaceutical led to the Sjöberg Prize

Benjamin L. Ebert, USA, receives this year’s Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer. His discovery of the mechanism that promotes protein breakdown in cancer cells may be vitally important to the future development of new pharmaceuticals.The story of this pharmaceutical begins with a tragedy as, in the 1950s and 1960s, pregnant women with severe morning sickness were sometimes given thalidomide. This caused a range of birth defects and the medication was removed from the market. Years later, thalidomide

Lower January sales for Clas Ohlson

Sales in January decreased by 9 per cent to 568 MSEK (625). Organic sales decreased by 5 per cent compared to the previous year. Sales in comparable units and local currency decreased by 4 per cent compared to the previous year. Online sales increased by 76 per cent to 70 MSEK (40). Compared to the same month last year the store network was reduced by 2 stores. At the end of the period the total number of stores was 227 (230).Distribution of sales Month Accumulated January Change May - January ChangeMkr

Targovax receives Fast-Track designation for ONCOS-102

· The US FDA grants ONCOS-102 Fast-Track designation for malignant pleural mesothelioma · Fast-Track opens the potential for expedited development and review with the US FDA Oslo, Norway 15 February 2021 – Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.   The US FDA granted Fast-Track designation to ONCOS-102 based on encouraging pre-clinical and

Aker Solutions ASA: Fourth-Quarter Results 2020

February 15, 2021 - Sound orderbook, strong market outlook, growth in energy transition. Aker Solutions and Kvaerner successfully completed the merger in the fourth quarter 2020. Fourth-quarter revenue ended at NOK 6.8 billion and the EBITDA at NOK 121 million, in line with previous communication. Despite the challenging backdrop of the COVID-19 pandemic, the order backlog grew 15 percent compared to in 2019 and ended at NOK 38 billion. The outlook for project sanctioning has improved for 2021 and 2022.4Q 2020 Financial Highlights · Revenues NOK 6.8 billion ex. special items ·

TietoEVRY to divest its Oil & Gas software business

TietoEVRY Corporation            INSIDE INFORMATION           15 February 2021, 8.00 EETTietoEVRY has reached an agreement with Aucerna, a Quorum Software affiliate, to sell its Oil & Gas software business. This divestment is part of the company’s strategy to seek focus and scale. Through this transaction, the Oil & Gas software business will have greater global market reach and growth opportunities. The agreement was reached at an enterprise value of EUR 155 million, implying an EV/Revenue multiple of approximately 3.2.   TietoEVRY’s Oil & Gas software business comprises hydrocarbon

There are no items matching the current filter
There are no more items matching the current filter
Back to top